Rep. Emily Randall Sells Abbott Laboratories (NYSE:ABT) Shares

Representative Emily Randall (D-Washington) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on February 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on January 6th. The trade occurred in the Representative’s “GARRET D. LEAHEY 2019 IRREVOCABLE F/B/O ALISON LEAHEY” account.

Representative Emily Randall also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 1/7/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Verizon Communications (NYSE:VZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Fortive (NYSE:FTV) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 1/6/2025.

Abbott Laboratories Stock Performance

Shares of ABT traded up $1.34 on Thursday, reaching $131.83. The company’s stock had a trading volume of 4,164,043 shares, compared to its average volume of 6,877,615. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $132.50. The stock has a market capitalization of $228.66 billion, a P/E ratio of 17.23, a PEG ratio of 2.39 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The stock’s 50 day simple moving average is $118.34 and its two-hundred day simple moving average is $115.71.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting the consensus estimate of $1.34. The firm had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.19 earnings per share. Research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.79%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 30.85%.

Insider Activity at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the transaction, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at approximately $16,152,064.50. This trade represents a 15.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ABT shares. Jefferies Financial Group lifted their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research note on Thursday, October 17th. Sanford C. Bernstein lifted their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Barclays reissued an “overweight” rating and issued a $158.00 price objective (up previously from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Piper Sandler increased their price target on shares of Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, October 17th. Finally, Argus raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Tuesday, January 28th. Four investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $133.06.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $2,373,461,000. Raymond James Financial Inc. purchased a new stake in Abbott Laboratories in the 4th quarter valued at approximately $635,056,000. Massachusetts Financial Services Co. MA lifted its stake in Abbott Laboratories by 25.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 13,319,347 shares of the healthcare product maker’s stock valued at $1,518,539,000 after buying an additional 2,711,586 shares in the last quarter. State Street Corp lifted its stake in Abbott Laboratories by 3.1% in the 3rd quarter. State Street Corp now owns 76,720,429 shares of the healthcare product maker’s stock valued at $8,746,896,000 after buying an additional 2,323,807 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in Abbott Laboratories by 27.6% in the 4th quarter. Invesco Ltd. now owns 9,018,429 shares of the healthcare product maker’s stock valued at $1,020,074,000 after buying an additional 1,948,329 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Representative Randall

Emily Randall (Democratic Party) is a member of the U.S. House, representing Washington’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Randall (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 6th Congressional District. She declared candidacy for the 2026 election.

Emily Randall was born in Port Orchard, Washington, and lives in Bremerton, Washington. Randall earned bachelor’s degrees in Spanish and women’s studies from Wellesley College in 2008. Her career experience includes working as a development professional with Wellesley College, the San Francisco AIDS Foundation, Planned Parenthood Federation of America, and Legal Voice.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.